What are the challenges in commercial non-tuberculous mycobacteria (NTM) drug discovery and how should we move forward? (original) (raw)

Profile image of Graham TimminsGraham Timmins

2019, Expert Opinion on Drug Discovery

Challenges facing the drug discovery pipeline for non-tuberculous mycobacteria

ARUNAVA DASGUPTA

Journal of Medical Microbiology, 2016

View PDFchevron_right

Challenges of NTM Drug Development

Joseph Falkinham

Frontiers in Microbiology, 2018

View PDFchevron_right

Drug Susceptibility Testing of Mycobacteria Isolated from Humans and Cattle from Selected Sites of Ethiopia

Mekonnen Tadesse

Journal of Tuberculosis Research, 2014

View PDFchevron_right

Are we overlooking infections owing to non-tuberculous mycobacteria during routine conventional laboratory investigations?

Deepthi Nair

International Journal of Mycobacteriology, 2012

View PDFchevron_right

Molecular Mycobacteriology and Expansion in Disease Diagnosis

PRAVEEN SHARMA

Indian Journal of Clinical Biochemistry, 2015

View PDFchevron_right

Structural Bioinformatic Approaches to the Discovery of New Antimycobacterial Drugs

Katherine Kantardjieff

Current Pharmaceutical Design, 2004

View PDFchevron_right

Drug susceptibility of Brazilian strains of Mycobacterium bovis using traditional and molecular techniques

Pedro Barrios

Memorias Do Instituto Oswaldo Cruz, 2004

View PDFchevron_right

Studies On Mycobacterium Chelonei

Francoise Portaels

Journal of Medical Microbiology, 1972

View PDFchevron_right

In Silico Screen and Structural Analysis Identifies Bacterial Kinase Inhibitors which Act with β-Lactams To Inhibit Mycobacterial Growth

Rob Striker

Molecular Pharmaceutics, 2018

View PDFchevron_right

Recommendations of the German Central Committee against Tuberculosis (DZK) and the German Respiratory Society (DGP) for the Diagnosis and Treatment of Non-tuberculous Mycobacterioses

Karl Schenkel

Pneumologie, 2016

View PDFchevron_right

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

Molecule Property Analyses of Active Compounds for Mycobacterium tuberculosis

phyo zin

Journal of Medicinal Chemistry, 2020

View PDFchevron_right

Contribution of the multidrug efflux pump LfrA to innate mycobacterial drug resistance

Howard Takiff

2000

View PDFchevron_right

Editorial: Drug-ability strategies for potential antimycobacterial candidate: opportunities and challenges

TAHZIBA HUSSAIN

Frontiers in Pharmacology, 2023

View PDFchevron_right

Mycobacterial Metabolic Pathways as Drug Targets: A Review

Jemal Adem

View PDFchevron_right

Management of mycobacterial infection and disease in children

Armando Corrêa

The Pediatric Infectious Disease Journal, 1995

View PDFchevron_right

Streptomycin-Starved Mycobacterium tuberculosis 18b, a Drug Discovery Tool for Latent Tuberculosis

Alfonso Mendoza-losana

Antimicrobial Agents and Chemotherapy, 2012

View PDFchevron_right

Discovery of the first potent and selective Mycobacterium tuberculosis Zmp1 inhibitor

francesca moraca

Bioorganic & Medicinal Chemistry Letters, 2014

View PDFchevron_right

Mycobacterium indicus pranii as stand-alone or adjunct immunotherapeutic in treatment of experimental animal tuberculosis

Umesh Gupta

The Indian Journal of Medical Research, 2011

View PDFchevron_right

Mycobacterial Cultures Contain Cell Size and Density Specific Sub-populations of Cells with Significant Differential Susceptibility to Antibiotics, Oxidative and Nitrite Stress

Atul Pradhan

Frontiers in Microbiology, 2017

View PDFchevron_right

Recent Advances in Mycobacterial Research

Vishwanath Venketaraman

Journal of Clinical Medicine

View PDFchevron_right

Preclinical Models of Nontuberculous Mycobacteria Infection for Early Drug Discovery and Vaccine Research

Elisa Rampacci

Pathogens

View PDFchevron_right

A Study of the Effectiveness of Two Common Fluoroquinolones on Mycobacterial Strains Isolated From Patients

seyyedreza moaddab

Mycobacterial Diseases, 2013

View PDFchevron_right

Activity of 16 Antimicrobial Agents Against Drug-Resistant Strains of Mycobacterium tuberculosis

L. Fattorini

Microbial Drug Resistance, 1999

View PDFchevron_right

Personalized medicine approach in mycobacterial disease

Mehdi Mirsaeidi

View PDFchevron_right

The Mycobacterial Membrane: A Novel Target Space for Anti-tubercular Drugs

Samuel Nyantakyi

Frontiers in microbiology, 2018

View PDFchevron_right

Assessment of potential antibacterial drug targets

Laura Diaz Saez

2016

View PDFchevron_right

Drug Susceptibility of the Mycobacterium Genus: In Vitro Tests and Clinical Implications

5798 Juan Antonio Dutari Rodriguez

Current Clinical Pharmacology, 2006

View PDFchevron_right

Data from Improved low molecular weight Myc-Max inhibitors

John Lazo

2023

View PDFchevron_right

A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis

Marcela Henao Tamayo

Nature Medicine, 2011

View PDFchevron_right

Mycobacterium tuberculosis Drug Resistance, Ghana

Muhammad Haroon

Emerging Infectious Diseases, 2006

View PDFchevron_right

Real time PCR for the rapid identification and drug susceptibility of Mycobacteria present in Bronchial washings

dhammika magana-arachchi

BMC Infectious Diseases, 2016

View PDFchevron_right

Recent advances in antibacterial drugs

Gurpreet Kaur Randhawa

International Journal of Applied and Basic Medical Research, 2013

View PDFchevron_right

An Experimental Model for the Rapid Screening of Compounds with Potential Use Against Mycobacteria

TATIANE COELHO

ASSAY and Drug Development Technologies, 2016

View PDFchevron_right

Geographical distribution and clinical relevance of non-tuberculous mycobacteria in Croatia

Mihaela Obrovac

The International Journal of Tuberculosis and Lung Disease, 2013

View PDFchevron_right

Editorial: Developing therapeutics for antimicrobial resistant pathogens

Bennett Amaechi

Frontiers in Cellular and Infection Microbiology, 2022

View PDFchevron_right

Medicine